about
Repeated biopsy in the detection of prostate cancer: when and how many coresLatest pharmacotherapy options for benign prostatic hyperplasia.Peyronie's disease and autoimmunity—a real-life clinical study and comprehensive review.Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines.Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.Efficacy and safety of dapoxetine in treatment of premature ejaculation: an evidence-based review.Time of onset of vardenafil orodispersible tablet in a real-life setting - looking beyond randomized clinical trials.Metabolic syndrome in white European men presenting for primary couple's infertility: investigation of the clinical and reproductive burden.Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy During Radical Cystectomy: A Sensitivity Curve Analysis.Lower urinary tract symptoms among Caucasian-European men who have sex with men: findings from a real-life survey.Long-term recovery of normal sexual function in testicular cancer survivorsAwareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs.First report on joint use of a Da Vinci® surgical system with transfer of surgical know-how between two public hospitals.Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium.Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostatesSpinal neuronal cannabinoid receptors mediate urodynamic effects of systemic fatty acid amide hydrolase (FAAH) inhibition in rats
P50
Q27000316-934BECDD-5387-4CB3-8D16-EBD50CF4DDA0Q38244053-0CC99D56-CBD6-48AD-B53B-873AAAA72CD0Q38335739-700B0654-0B8C-40CE-9A20-3F03F349B560Q38672172-5071A387-A3BC-4633-9507-DF04FEE2F585Q38845916-F9275E9B-520C-4335-8800-970B392E1B4EQ38908136-E87D6126-33E4-4144-B878-A91626293A43Q38994942-E9D35F1B-8407-4BF3-954E-5ABBA58726CDQ39638677-1DFE2B1C-B966-434B-83A4-FC3F592480EAQ40194329-05918F13-929D-4E4F-B829-4F89A351CD95Q40490597-D3C02A91-5A41-476A-ADD6-218D1474EFE3Q40796018-7DBB01AE-388E-4EDA-9274-27F2C73476E6Q41758679-917E482E-6B27-47A9-B3AF-F51FD6C916D9Q42666982-A8BFF29C-A12C-42A0-86B1-5FD2627B6F98Q50058102-68E711A3-F5AA-46C3-B012-C05EBEC0D7F0Q85642964-BF4FDBD0-E8C5-4FDA-A347-DCD7F3131EDAQ86955260-91C965C6-91A7-4A05-AB57-41B8F0E7AEE6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Giovanni La Croce
@ast
Giovanni La Croce
@en
Giovanni La Croce
@es
Giovanni La Croce
@nl
type
label
Giovanni La Croce
@ast
Giovanni La Croce
@en
Giovanni La Croce
@es
Giovanni La Croce
@nl
prefLabel
Giovanni La Croce
@ast
Giovanni La Croce
@en
Giovanni La Croce
@es
Giovanni La Croce
@nl
P106
P1153
55636431700
P21
P31
P496
0000-0001-6209-8670